Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Labour Govt Would Boost Health Spending, Put Pressure On Drug Prices

Out Goes R&D Credit, In Comes Compulsory Licensing

Executive Summary

The election manifesto produced by the Labour Party offers something for everyone, from the dropping of prescription charges and a boost for health care spending to more use of compulsory licensing and the building of a state-owned generics factory to make medicines more affordable.

You may also be interested in...



UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

UK Conservatives Promise ‘Innovative Medicines Fund’ If Re-Elected

More money to pay for innovative new medicines, more cash and support for the life sciences sector, and Brexit by 31 January 2020 are among promises made in the Conservative Party’s election platform. 

Coronavirus Notebook: WHO Says Extra Vaccine Boosters Confer Some Limited Benefits, Emergex & Zosano Link Up On T Cell Vaccine Patch

International regulators have issued an updated statement on the benefits and safety of COVID-19 vaccines for use by health professionals, while the UK BioIndustry Association has welcomed a MAb licensing deal between AstraZeneca and UK-based biotech firm RQ Bio.

Topics

UsernamePublicRestriction

Register

PS141249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel